RELIEF THERAPEUTICS Valuation
| 0QKQ Stock | 2.17 0.01 0.46% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. RELIEF THERAPEUTICS holds a recent Real Value of USD2.03 per share. The prevailing price of the company is USD2.17. Our model determines the value of RELIEF THERAPEUTICS from inspecting the company fundamentals such as return on equity of -0.39, and Operating Margin of (1.27) % as well as reviewing its technical indicators and probability of bankruptcy.
Enterprise Value 14 M | Price Sales 162.6857 |
Overvalued
Today
Please note that RELIEF THERAPEUTICS's price fluctuation is dangerous at this time. Calculation of the real value of RELIEF THERAPEUTICS is based on 3 months time horizon. Increasing RELIEF THERAPEUTICS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the RELIEF stock is determined by what a typical buyer is willing to pay for full or partial control of RELIEF THERAPEUTICS Holding. Since RELIEF THERAPEUTICS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of RELIEF Stock. However, RELIEF THERAPEUTICS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.17 | Real 2.03 | Hype 2.16 | Naive 2.2 |
The intrinsic value of RELIEF THERAPEUTICS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence RELIEF THERAPEUTICS's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of RELIEF THERAPEUTICS Holding helps investors to forecast how RELIEF stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of RELIEF THERAPEUTICS more accurately as focusing exclusively on RELIEF THERAPEUTICS's fundamentals will not take into account other important factors: RELIEF THERAPEUTICS Cash |
|
RELIEF THERAPEUTICS Total Value Analysis
RELIEF THERAPEUTICS Holding is presently projected to have takeover price of 13.96 M with market capitalization of 1.37 B, debt of 2.14 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the RELIEF THERAPEUTICS fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.96 M | 1.37 B | 2.14 M |
RELIEF THERAPEUTICS Investor Information
About 23.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 0.01. RELIEF THERAPEUTICS had not issued any dividends in recent years. The entity had 0.0025:1 split on the 5th of May 2023. Based on the key indicators related to RELIEF THERAPEUTICS's liquidity, profitability, solvency, and operating efficiency, RELIEF THERAPEUTICS Holding is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.RELIEF THERAPEUTICS Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. RELIEF THERAPEUTICS has an asset utilization ratio of 15.81 percent. This implies that the Company is making USD0.16 for each dollar of assets. An increasing asset utilization means that RELIEF THERAPEUTICS Holding is more efficient with each dollar of assets it utilizes for everyday operations.RELIEF THERAPEUTICS Ownership Allocation
RELIEF THERAPEUTICS owns a total of 633.95 Million outstanding shares. Roughly 75.91 pct. of RELIEF THERAPEUTICS outstanding shares are held by general public with 0.99 % owned by insiders and only 23.1 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.RELIEF THERAPEUTICS Profitability Analysis
The company reported the revenue of 8.42 M. Net Loss for the year was (17.12 M) with profit before overhead, payroll, taxes, and interest of 5.84 M.About RELIEF THERAPEUTICS Valuation
The stock valuation mechanism determines RELIEF THERAPEUTICS's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of RELIEF THERAPEUTICS based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of RELIEF THERAPEUTICS. We calculate exposure to RELIEF THERAPEUTICS's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of RELIEF THERAPEUTICS's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 5.8 M | 4 M |
Additional Tools for RELIEF Stock Analysis
When running RELIEF THERAPEUTICS's price analysis, check to measure RELIEF THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RELIEF THERAPEUTICS is operating at the current time. Most of RELIEF THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of RELIEF THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RELIEF THERAPEUTICS's price. Additionally, you may evaluate how the addition of RELIEF THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.